[A specialised consultation for children and young adults with trisomy 21]

Area of Science:

• Medical science
• Genetics
• Pediatrics

Background:

• Trisomy 21, commonly known as Down syndrome, is a genetic disorder associated with intellectual disability, distinctive facial features, and other health issues.
• Historically, the life expectancy for individuals with Down syndrome was significantly lower, with an average of only 9 years in 1929.

Purpose of the Study:

• To highlight the significant increase in life expectancy for individuals with trisomy 21 over recent decades.
• To identify factors contributing to this improved longevity.
• To emphasize the ongoing need for adapted medical monitoring throughout the lifespan, particularly from puberty onwards.

Main Methods:

• This study is a review of existing data and medical literature concerning trisomy 21.
• Analysis of historical and current life expectancy statistics for individuals with Down syndrome.
• Identification of advancements in medical care, diagnosis, and therapeutic interventions.

Main Results:

• Life expectancy for individuals with trisomy 21 has dramatically increased, with over 50% now living beyond 55 years.
• Key factors contributing to this increase include improved access to healthcare, enhanced medical diagnoses, and greater availability of physical and psychological stimulation.
• Despite these advances, the systematic nature of medical monitoring tends to decrease as individuals with Down syndrome age, even though the risk of certain complications rises after puberty.

Conclusions:

• The improved life expectancy for individuals with trisomy 21 represents a significant public health achievement.
• Continued, adapted medical monitoring is crucial, especially during adolescence and adulthood, to manage age-related complications.
• Specialized consultations for trisomy 21 are vital for ensuring accessible and appropriate healthcare pathways.